Issue: June 2017
June 07, 2017
1 min read
Save

Trial Scorecard: EDIFY

Issue: June 2017
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Researchers evaluated heart rate and cardiac function in patients with HF with preserved ejection fraction treated with ivabradine (Corlanor, Amgen).

Trial Scorecards: EDIFY